(Q38590471)

4 September 2017

Targeted therapies in bladder cancer: an overview of in vivo research (English)

1 reference

4 September 2017

1 reference

Kim E M van Kessel

1

1 reference

4 September 2017

Tahlita C M Zuiverloon

2

1 reference

4 September 2017

Arnout R Alberts

3

1 reference

4 September 2017

Joost L Boormans

4

1 reference

4 September 2017

Ellen C Zwarthoff

5

1 reference

4 September 2017

language of work or name

English

0 references

publication date

22 September 2015

1 reference

4 September 2017

Nature Reviews Urology

1 reference

4 September 2017

12

1 reference

4 September 2017

12

1 reference

4 September 2017

681-694

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2015.231

4 September 2017

0 references

cites work

The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A history of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Targeted therapies in urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Contributions of human tumor xenografts to anticancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Targeted therapies in bladder cancer--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

canSAR: an integrated cancer public translational research and drug discovery resource

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Identification of targetable FGFR gene fusions in diverse cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

VEGF as a key mediator of angiogenesis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Inactivation of p53 and Pten promotes invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Phase II study of everolimus in metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Downregulation of integrin-linked kinase inhibits epithelial-to-mesenchymal transition and metastasis in bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Inhibition of bladder tumour growth by histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Promotion of bladder cancer development and progression by androgen receptor signals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

What we could do now: molecular pathology of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Mutations in apoptosis genes: a pathogenetic factor for human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Antisense oligonucleotide targeting Livin induces apoptosis of human bladder cancer cell via a mechanism involving caspase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Targeting the eukaryotic translation initiation factor 4E for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

CD24 is an effector of HIF-1-driven primary tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Additive antitumoral effect of interleukin-12 gene therapy and chemotherapy in the treatment of urothelial bladder cancer in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Emerging immunotherapies for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Viruses in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

From virotherapy to oncolytic immunotherapy: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Differences in the composition of the human antibody repertoire by B cell subsets in the blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

The effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Targeting of alpha-v integrins reduces malignancy of bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Allyl isothiocyanate-rich mustard seed powder inhibits bladder cancer growth and muscle invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

The principal urinary metabolite of allyl isothiocyanate, N-acetyl-S-(N-allylthiocarbamoyl)cysteine, inhibits the growth and muscle invasion of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Small interfering RNA targeting integrin-linked kinase inhibited the growth and induced apoptosis in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

shRNA targeting PLCε inhibits bladder cancer cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Thrombomodulin expression regulates tumorigenesis in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Effect of nitroxoline on angiogenesis and growth of human bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Cyclooxygenase 2-dependent and independent activation of Akt through casein kinase 2α contributes to human bladder cancer cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Activation of nerve growth factor-induced B alpha by methylene-substituted diindolylmethanes in bladder cancer cells induces apoptosis and inhibits tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Intravesical instillation of c-MYC inhibitor KSI-3716 suppresses orthotopic bladder tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Inhibition of nitric oxide is a good therapeutic target for bladder tumors that express iNOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Target expression of Staphylococcus enterotoxin A from an oncolytic adenovirus suppresses mouse bladder tumor growth and recruits CD3+ T cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

TGF-β-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

RNA interference targeting adrenomedullin induces apoptosis and reduces the growth of human bladder urothelial cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

The inhibition of human bladder cancer growth by calcium carbonate/CaIP6 nanocomposite particles delivering AIB1 siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Overexpression of immunoglobulin G prompts cell proliferation and inhibits cell apoptosis in human urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

BCMab1, a monoclonal antibody against aberrantly glycosylated integrin α3β1, has potent antitumor activity of bladder cancer in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Knockdown of a novel lincRNA AATBC suppresses proliferation and induces apoptosis in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Tyrosine kinases as targets for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Combined use of Anti-VEGF and Anti-EGFR Monoclonal Antibodies with Photodynamic Therapy Suppresses Tumor Growth in an In vivo Tumor Model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

siRNA-mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses the growth and metastasis of mouse bladder carcinoma in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Androgen receptor is a potential therapeutic target for bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Could MPDL3280A offer a therapeutic breakthrough in metastatic bladder cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.231

Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer

31 March 2020

1 reference

12 December 2020

Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma

1 reference

12 December 2020

Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1.

1 reference

12 December 2020

A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.

1 reference

12 December 2020

Targeted therapies: a new generation of cancer treatments.

1 reference

12 December 2020

Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2015.231

1 reference

Dimensions Publication ID

4 September 2017

0 references

1 reference